3:I[231,["231","static/chunks/231-0fefb1d35a503081.js","669","static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js"],""]
4:I[9275,[],""]
6:I[1343,[],""]
7:I[8173,["231","static/chunks/231-0fefb1d35a503081.js","410","static/chunks/410-427e639415368772.js","185","static/chunks/app/layout-cc68188960cc2107.js"],"Image"]
2:T594,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does CYC do?","acceptedAnswer":{"@type":"Answer","text":"Cyclopharm Limited develops and commercialises nuclear medicine products, primarily TechneGas (TechneLite), which is an imaging agent used to diagnose pulmonary embolism through lung ventilation scans. They manufacture and distribute this product globally, with a key focus on the US market."}},{"@type":"Question","name":"Is CYC a good investment?","acceptedAnswer":{"@type":"Answer","text":"CYC presents a high-growth, high-risk investment opportunity. Its potential lies in the successful global rollout of TechneGas, particularly in the US, which could drive significant revenue growth. However, as a small-cap healthcare company, it faces commercialisation challenges, regulatory hurdles, and intense competition, making it a speculative investment with share price volatility likely."}},{"@type":"Question","name":"What drives CYC's share price?","acceptedAnswer":{"@type":"Answer","text":"CYC's share price is primarily driven by announcements related to its US commercialisation progress, including sales figures, clinic adoptions, and reimbursement updates. Regulatory approvals in new markets, clinical data updates, new distribution partnerships, and overall financial performance (especially progress towards consistent profitability) are also key drivers."}}]}5:["ticker","CYC","d"]
0:["expxC_2cvqaJFzWCHYH4M",[[["",{"children":["asx",{"children":[["ticker","CYC","d"],{"children":["__PAGE__?{\"ticker\":\"CYC\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","CYC","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Cyclopharm Limited"," (","CYC",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Cyclopharm Limited (ASX: CYC) is an Australian-based company specializing in nuclear medicine products. Its flagship product, TechneGas (marketed as TechneLite in some regions), is a lung ventilation imaging agent used primarily for the diagnosis of pulmonary embolism. The company operates globally, with a significant focus on commercialising TechneGas in major markets like the United States following recent regulatory approvals."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$107M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"Price Chart (TradingView)"}],["$","div",null,{"className":"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400","children":["Embed TradingView widget here for ","CYC",". The production version should load live pricing and technical indicators."]}]]}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Cyclopharm is currently in a pivotal commercialisation phase, particularly following its FDA approval for TechneGas in the United States in 2021. The company has established distribution networks and is focused on driving adoption of its product, which offers a robust alternative to older imaging methods for diagnosing pulmonary embolism. Recent performance has shown a ramp-up in sales and manufacturing capabilities, though profitability can be variable as it invests heavily in market penetration and operational scaling. Key metrics to watch include quarterly sales growth, US market penetration rates, and progress on reimbursement pathways.",{"children":"Cyclopharm is currently in a pivotal commercialisation phase, particularly following its FDA approval for TechneGas in the United States in 2021. The company has established distribution networks and is focused on driving adoption of its product, which offers a robust alternative to older imaging methods for diagnosing pulmonary embolism. Recent performance has shown a ramp-up in sales and manufacturing capabilities, though profitability can be variable as it invests heavily in market penetration and operational scaling. Key metrics to watch include quarterly sales growth, US market penetration rates, and progress on reimbursement pathways."}],["$","p","The primary growth outlook for Cyclopharm is predicated on successful market penetration and adoption of TechneGas in the highly lucrative US market, which represents a significant expansion opportunity. Upcoming catalysts include updates on sales volumes, new distribution agreements, and further regulatory approvals or expanded indications in other jurisdictions. The strategic direction involves leveraging its proprietary technology to become a global leader in lung ventilation imaging, with potential future product developments or geographic expansions also on the horizon. Given its small market cap, CYC remains a speculative investment with growth highly dependent on execution in its target markets.",{"children":"The primary growth outlook for Cyclopharm is predicated on successful market penetration and adoption of TechneGas in the highly lucrative US market, which represents a significant expansion opportunity. Upcoming catalysts include updates on sales volumes, new distribution agreements, and further regulatory approvals or expanded indications in other jurisdictions. The strategic direction involves leveraging its proprietary technology to become a global leader in lung ventilation imaging, with potential future product developments or geographic expansions also on the horizon. Given its small market cap, CYC remains a speculative investment with growth highly dependent on execution in its target markets."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Rapid and widespread adoption of TechneGas in the US market, exceeding current expectations, driven by its superior diagnostic performance and logistical advantages.",{"children":["• ","Rapid and widespread adoption of TechneGas in the US market, exceeding current expectations, driven by its superior diagnostic performance and logistical advantages."]}],["$","li","Successful expansion into new international markets or securing additional regulatory approvals for expanded product indications, significantly broadening its addressable market.",{"children":["• ","Successful expansion into new international markets or securing additional regulatory approvals for expanded product indications, significantly broadening its addressable market."]}],["$","li","Achievement of consistent profitability and positive cash flow through economies of scale and strong revenue growth, attracting institutional investment and re-rating of the stock.",{"children":["• ","Achievement of consistent profitability and positive cash flow through economies of scale and strong revenue growth, attracting institutional investment and re-rating of the stock."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Slower-than-anticipated market penetration and adoption of TechneGas in the US due to reimbursement challenges, strong competition from existing alternatives, or physician inertia.",{"children":["• ","Slower-than-anticipated market penetration and adoption of TechneGas in the US due to reimbursement challenges, strong competition from existing alternatives, or physician inertia."]}],["$","li","Manufacturing or supply chain disruptions impacting product availability, leading to lost sales opportunities or increased operational costs.",{"children":["• ","Manufacturing or supply chain disruptions impacting product availability, leading to lost sales opportunities or increased operational costs."]}],["$","li","Failure to achieve consistent profitability, requiring further capital raises that could dilute existing shareholders, especially given its small-cap nature.",{"children":["• ","Failure to achieve consistent profitability, requiring further capital raises that could dilute existing shareholders, especially given its small-cap nature."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Quarterly Activities Report"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Highlights production updates, capital allocation priorities, and FY guidance commentary."}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Investor Presentation"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Strategic outlook with market positioning and growth pipeline."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does CYC do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does CYC do?"}],["$","p",null,{"className":"text-slate-400","children":"Cyclopharm Limited develops and commercialises nuclear medicine products, primarily TechneGas (TechneLite), which is an imaging agent used to diagnose pulmonary embolism through lung ventilation scans. They manufacture and distribute this product globally, with a key focus on the US market."}]]}],["$","div","Is CYC a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is CYC a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"CYC presents a high-growth, high-risk investment opportunity. Its potential lies in the successful global rollout of TechneGas, particularly in the US, which could drive significant revenue growth. However, as a small-cap healthcare company, it faces commercialisation challenges, regulatory hurdles, and intense competition, making it a speculative investment with share price volatility likely."}]]}],["$","div","What drives CYC's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives CYC's share price?"}],["$","p",null,{"className":"text-slate-400","children":"CYC's share price is primarily driven by announcements related to its US commercialisation progress, including sales figures, clinic adoptions, and reimbursement updates. Regulatory approvals in new markets, clinical data updates, new distribution partnerships, and overall financial performance (especially progress towards consistent profitability) are also key drivers."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.53"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["30.0","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$107M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"18/01/2007"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L3",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","285.40"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["9.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$140B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","1.66"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["14.7","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$2.4B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.09"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["37.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$5","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L3",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L7",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L3","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L3","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L3","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L3","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L3","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L3","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 sm:flex","children":[["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden","children":[["$","span",null,{"children":"AI market insights for ASX investors"}],["$","$L3",null,{"href":"/screener","className":"text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L3",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/7c1fda61599f9f98.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L8"]]]]]
8:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"CYC share price, analysis & company profile - Cyclopharm Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest CYC share price overview, what Cyclopharm Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/CYC/"}],["$","meta","5",{"property":"og:title","content":"CYC share price, analysis & company profile - Cyclopharm Limited"}],["$","meta","6",{"property":"og:description","content":"Latest CYC share price overview, what Cyclopharm Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/CYC/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"CYC share price, analysis & company profile - Cyclopharm Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest CYC share price overview, what Cyclopharm Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
